202 related articles for article (PubMed ID: 19520676)
1. Economic and practical aspects of thromboprophylaxis with unfractionated and low-molecular-weight heparins in hospitalized medical patients.
Pineo GF; Hull RD
Clin Appl Thromb Hemost; 2009 Oct; 15(5):489-500. PubMed ID: 19520676
[TBL] [Abstract][Full Text] [Related]
2. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
3. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients--a pharmacoeconomic analysis.
Wilbur K; Lynd LD; Sadatsafavi M
Clin Appl Thromb Hemost; 2011 Oct; 17(5):454-65. PubMed ID: 20699258
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary embolism in medical patients: improved diagnosis and the role of low-molecular-weight heparin in prevention and treatment.
Merli GJ
J Thromb Thrombolysis; 2004 Oct; 18(2):117-25. PubMed ID: 15789178
[TBL] [Abstract][Full Text] [Related]
7. Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients.
Haas S
Semin Thromb Hemost; 1999; 25 Suppl 3():101-5. PubMed ID: 10549724
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.
McGarry LJ; Thompson D; Weinstein MC; Goldhaber SZ
Am J Manag Care; 2004 Sep; 10(9):632-42. PubMed ID: 15515996
[TBL] [Abstract][Full Text] [Related]
9. Venous thromboembolic risk and its prevention in hospitalized medical patients.
Haas SK
Semin Thromb Hemost; 2002 Dec; 28(6):577-84. PubMed ID: 12536351
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of prolonged thromboprophylaxis after cancer surgery.
Bradley CT; Brasel KJ; Miller JJ; Pappas SG
Ann Surg Oncol; 2010 Jan; 17(1):31-9. PubMed ID: 19707830
[TBL] [Abstract][Full Text] [Related]
11. Building effective prophylaxis of deep vein thrombosis in the outpatient setting.
Agnelli G; Taliani MR; Verso M
Blood Coagul Fibrinolysis; 1999 Aug; 10 Suppl 2():S29-35. PubMed ID: 10493228
[TBL] [Abstract][Full Text] [Related]
12. The rationale for long-term prophylaxis of venous thromboembolism.
Agnelli G; Mancini GB; Biagini D
Orthopedics; 2000 Jun; 23(6 Suppl):s643-6. PubMed ID: 10875429
[TBL] [Abstract][Full Text] [Related]
13. Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis.
Shorr AF; Jackson WL; Weiss BM; Moores LK
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):309-16. PubMed ID: 17473570
[TBL] [Abstract][Full Text] [Related]
14. VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients.
Cohen AT; Nandini B; Wills JO; Ota S
Thromb Res; 2010 Apr; 125 Suppl 2():S21-9. PubMed ID: 20434000
[TBL] [Abstract][Full Text] [Related]
15. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
16. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
Bell GK; Goldhaber SZ
Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
[TBL] [Abstract][Full Text] [Related]
18. Low molecular weight heparins: the optimal treatment for venous thromboembolism.
Daskalopoulos ME; Daskalopoulou SS; Liapis CD
Curr Med Res Opin; 2004 Jul; 20(7):1001-5. PubMed ID: 15265244
[TBL] [Abstract][Full Text] [Related]
19. Management of venous thromboembolic disease. The impact of low-molecular-weight heparin.
Tapson VF; Hull RD
Clin Chest Med; 1995 Jun; 16(2):281-94. PubMed ID: 7656540
[TBL] [Abstract][Full Text] [Related]
20. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
Kamphuisen PW; Agnelli G
Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
